Authors

Latest:

ASH 2010: Data Support Escalated BEACOPP as Superior Method of Tumor Control in Early Unfavorable Hodgkin Lymphoma

In patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.

By Barbara Daly, PhD, RN, FAAN

Latest:

Preparing Nurses for Advanced Practice in Oncology and Palliative Care

Barbara Daly, PhD, RN, FAAN, and Helen Foley, MSN, AOCNS®, offer highlights of their institution's oncology and palliative care program, which successfully prepares graduates to assume advanced practice roles in these important areas.

By Barbara J. Gitlitz, MD, Stephen V. Liu, MD

Latest:

USC Works With "Dream Team" to Deliver Promise of Epigenetic Therapy to Clinical Practice

Barbara J. Gitlitz, MD, Stephen V. Liu, MD, and Peter A. Jones, PhD, DSc, from the USC Norris Comprehensive Cancer Center, describe efforts to translate promising epigenetic research into clinical practice.

By Bonnie Gillis

Latest:

T-DM1 Achieves Longer Progression-Free Survival vs. Standard Therapy in HER2+ Metastatic Breast Cancer

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

By Bradley Schmidt

Latest:

Where Do We Go from Here? A Health 2.0 Progress Report

Healthcare consumers may be the driving force behind Health 2.0, but are they really in control? And who knows what the final destination will be?

By Brenda Ernst, MD

Latest:

Mindfulness Based Resilience and Self-Care: Why it Matters in Oncology

The Buddhist teaching that "Your true work is to discover your world and then with all your heart give yourself to it" can certainly be applied to oncology.

By Christin Melton

Latest:

Home Sales: It%u2019s A Buyer%u2019s Market

This year, most Americans have seen the value of their home drop faster than a lead weight. If you purchased your home in the last 10 years, during the housing boom, you will likely find that it is worth less today than what you paid for it%u2014and in some cases less than what you still owe.

By Christina Loguidice

Latest:

Personalized Medicine Is Gaining Momentum in Advanced Endometrial Cancer

Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.

By Christina T. Loguidice

Latest:

Optimizing Outcomes With ADCs in Breast Cancer Requires a Tactical Approach

Antibody-drug conjugates are innovative and effective therapeutic agents that have transformed the treatment landscape for patients with HER2-positive breast cancer and triple-negative breast cancer.

By Daniel C. Cho, MD

Latest:

Sequencing VEGFR-Targeted and mTOR-Targeted Therapy in Advanced Renal Cell Carcinoma

With 8 therapies approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced renal cell carcinoma (RCC), practitioners are faced with the challenge of selecting the most appropriate therapies for their patients within this crowded therapeutic landscape.

By Dennie V. Jones, Jr., MD

Latest:

The Importance of Mentoring in Preparing the Next Generation of Oncologists

Since the time of Hippocrates, practicing the art of medicine has involved the passage of knowledge and experience from one generation of practitioners to the next.

By Diane West

Latest:

The Rapid Reporter: April 2007

This month we report on presentations made at the BIO (Biotechnology Industry Organization)CEO & Investor Conference (February 11-14, 2007, New York, NY).

By E. Roy Berger, MD, FACP

Latest:

Immunotherapy

Novel immunotherapy approaches to metastatic prostate cancer: Stimulating the immune response ex vivo with autologous antigen presenting cells.

By Ed Rabinowitz

Latest:

Trekking Treatment

By Eileen Koutnik-Fotopoulos

Latest:

Integrative Medicine and Cancer Treatment

Linda A. Lee, MD, director of the Johns Hopkins Integrative Medicine & Digestive Center (JHIMDC) in Lutherville, Maryland, believes that an integrative approach to treating conditions and symptoms helps improve patients' quality of life.

By Elizabeth Freid Vocke

Latest:

Are Your Patients in Clinical Trials? US Oncology Surveys Oncologists

Participation in clinical trial research is essential to continued improvement in cancer care. Yet, fewer than 10% of U.S. adults enroll in trials. A recent US OncologyÃ¢ï¿½ï¿½sponsored survey found that most oncologists remain optimistic about the future of clinical trial research. We discuss obstacles to clinical trial enrollment with Nicholas Vogelzang, MD, and Matthew Galsky, MD, of the Comprehensive CancerCenters of Nevada.

By Elizabeth J. Mills

Latest:

Flash Findings

Fast biotech facts and figures. In this issue: 1) Cancer Risk Factors and Mortality 2) Bladder Cancer 3) Testicular Cancer 4) Breast Cancer

By Elizabeth Mills

Latest:

The Virtual Window: Clinical Trial Reports--March 2007

Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.

By Eric M. Genden, MD, Brett Miles, MD, DDS, Marshall Posner, MD

Latest:

Personalizing Treatment for HPV-Related Head and Neck Cancer

Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.

By Gina Columbus

Latest:

Findings Support Early Use of CD19 CAR T-Cell Therapy in Relapsed B-cell ALL

Low disease burden prior to treatment with CD19-specific chimeric antigen receptor T-cell therapy appears to be a positive prognostic factor for long-term survival outcomes of patients with relapsed B-cell acute lymphoblastic leukemia.